NCT06970756View on ClinicalTrials.gov

A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

November 27, 2025

Study Completion Date

July 10, 2026

Conditions
Pneumococcal Diseases
Interventions
BIOLOGICAL

26-valent Pneumococcal Conjugate Vaccine

Subjects were treated with a single intramuscular injection of 26-valent Pneumococcal Conjugate Vaccine.

BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

Subjects were treated with a single intramuscular injection of 13-valent Pneumococcal Conjugate Vaccine.

Trial Locations (1)

3124

Emeritus Research, Melbourne

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY